TY - JOUR
TI - Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib
AU - Koutsoukos, K.
AU - Bamias, A.
AU - Tzannis, K.
AU - Montaño, M.E.
AU - Bozionelou, V.
AU - Christodoulou, C.
AU - Stefanou, D.
AU - Kalofonos, H.
AU - Duran, I.
AU - Papazisis, K.
JO - OncoTargets and therapy
PY - 2017
VL - 10
TODO - null
SP - 4885-4893
PB - Dove Medical Press Ltd
SN - null
TODO - 10.2147/OTT.S141260
TODO - everolimus;  gamma glutamyltransferase;  pazopanib, acute kidney failure;  adult;  aged;  alopecia;  anemia;  arthralgia;  Article;  bleeding;  bone pain;  cancer prognosis;  clinical article;  diarrhea;  drug fatality;  drug safety;  drug withdrawal;  edema;  experience;  fatigue;  female;  fever;  Greece;  human;  hypercalcemia;  hyperlipidemia;  intermediate risk population;  kidney metastasis;  loss of appetite;  lung embolism;  male;  medical record review;  mucosa inflammation;  nephrectomy;  overall survival;  pleura effusion;  pneumonia;  progression free survival;  proteinuria;  rash;  retrospective study;  Spain;  stomach hemorrhage;  stomatitis;  tooth pain;  treatment failure;  treatment outcome;  unspecified side effect;  very elderly
TODO - Aim: We aimed to provide real-life data on the outcomes of metastatic renal cell carcinoma (mRCC) patients treated with everolimus as second-line treatment after failure of first-line pazopanib. Patients and methods: Data from the medical charts of mRCC patients from 8 centers in Greece and Spain were ed. All patients had received or were continuing to receive second-line everolimus treatment after failure of first-line treatment with pazopanib. No other previous therapies were allowed. The primary end point was the determination of progression-free survival (PFS). Results: In total, 31 patients were enrolled. Of these, 26% had performance status (PS).0, 88% were of intermediate/poor Memorial Sloan-Kettering Cancer Center (MSKCC) risk group, and only 61% had undergone prior nephrectomy. Median PFS was 3.48 months (95% CI: 2.37-5.06 months). Median overall survival (OS) from everolimus initiation was 8.9 months (95% CI: 6.47-13.14 months). Median OS from pazopanib initiation was 14.78 months (95% CI: 10.54-19.08 months). Furthermore, 32% of patients temporarily discontinued everolimus due to adverse events (AEs), and 22% of patients discontinued everolimus permanently due to toxicity. Most common toxicities were anemia (29%), stomatitis (26%), pneumonitis (19%), and fatigue (10%). Moreover, 14 AEs (27%) were graded as 3 or 4 and were reported by 13 patients (42%). Conclusion: This study provides data exclusively on the sequence pazopanib-everolimus in mRCC. Everolimus has a favorable safety profile and is active. The short PFS and OS could be attributed to the fact that the pazopanib-everolimus sequence was mainly offered to patients with adverse prognostic features, resulting in a modest increase in the combined OS of our population. © 2017 Koutsoukos et al.
ER -